Literature DB >> 25655603

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

Bruno Paiva1, Luis A Corchete2, Maria-Belen Vidriales2, Ramón García-Sanz2, Jose J Perez2, Irene Aires-Mejia2, Maria-Luz Sanchez3, Paloma Barcena3, Diego Alignani1, Cristina Jimenez2, Maria-Eugenia Sarasquete2, María-Victoria Mateos2, Enrique M Ocio2, Noemi Puig2, Fernando Escalante4, José Hernández5, Rebeca Cuello6, Alfonso García de Coca6, Magdalena Sierra7, Maria-Carmen Montes7, Tomás J González-López8, Josefina Galende9, Abelardo Bárez10, José Alonso11, Emilia Pardal12, Alberto Orfao3, Norma C Gutierrez2, Jesús F San Miguel1.   

Abstract

Although information about the molecular pathogenesis of Waldenström macroglobulinemia (WM) has significantly advanced, the precise cell of origin and the mechanisms behind WM transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS) remain undetermined. Here, we undertook an integrative phenotypic, molecular, and genomic approach to study clonal B cells from newly diagnosed patients with IgM MGUS (n = 22), smoldering (n = 16), and symptomatic WM (n = 11). Through principal component analysis of multidimensional flow cytometry data, we demonstrated highly overlapping phenotypic profiles for clonal B cells from IgM MGUS, smoldering, and symptomatic WM patients. Similarly, virtually no genes were significantly deregulated between fluorescence-activated cell sorter-sorted clonal B cells from the 3 disease groups. Interestingly, the transcriptome of the Waldenström B-cell clone was highly different than that of normal CD25(-)CD22(+) B cells, whereas significantly less genes were differentially expressed and specific WM pathways normalized once the transcriptome of the Waldenström B-cell clone was compared with its normal phenotypic (CD25(+)CD22(+low)) B-cell counterpart. The frequency of specific copy number abnormalities [+4, del(6q23.3-6q25.3), +12, and +18q11-18q23] progressively increased from IgM MGUS and smoldering WM vs symptomatic WM (18% vs 20% and 73%, respectively; P = .008), suggesting a multistep transformation of clonal B cells that, albeit benign (ie, IgM MGUS and smoldering WM), already harbor the phenotypic and molecular signatures of the malignant Waldenström clone.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25655603     DOI: 10.1182/blood-2014-09-602565

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4.

Authors:  Maria Luisa Guerrera; Nickolas Tsakmaklis; Lian Xu; Guang Yang; Maria Demos; Amanda Kofides; Gloria G Chan; Robert J Manning; Xia Liu; Jiaji G Chen; Manit Munshi; Christopher J Patterson; Jorge J Castillo; Toni Dubeau; Joshua Gustine; Ruben D Carrasco; Luca Arcaini; Marzia Varettoni; Mario Cazzola; Steven P Treon; Zachary R Hunter
Journal:  Haematologica       Date:  2018-03-29       Impact factor: 9.941

2.  TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.

Authors:  Jennifer Shrimpton; Matthew A Care; Jonathan Carmichael; Kieran Walker; Paul Evans; Charlotte Evans; Ruth de Tute; Roger Owen; Reuben M Tooze; Gina M Doody
Journal:  Blood Adv       Date:  2020-06-23

3.  IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.

Authors:  Abdul Hamid Bazarbachi; Hervé Avet-Loiseau; Raphael Szalat; Anil Aktas Samur; Zachary Hunter; Masood Shammas; Jill Corre; Mariateresa Fulciniti; Kenneth C Anderson; Giovanni Parmigiani; Steven P Treon; Mohamad Mohty; Nikhil C Munshi; Mehmet Kemal Samur
Journal:  Blood       Date:  2021-11-18       Impact factor: 22.113

4.  Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

Authors:  Kavita M Dhodapkar; Madhav V Dhodapkar; Akhilesh Kaushal; Ajay K Nooka; Allison R Carr; Katherine E Pendleton; Benjamin G Barwick; Julia Manalo; Samuel S McCachren; Vikas A Gupta; Nisha S Joseph; Craig C Hofmeister; Jonathan L Kaufman; Leonard T Heffner; Stephen M Ansell; Lawrence H Boise; Sagar Lonial
Journal:  Blood Cancer Discov       Date:  2021-09-01

Review 5.  Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.

Authors:  Prashant Kapoor; Jonas Paludo; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2016-03

Review 6.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

7.  Differentiation stage of myeloma plasma cells: biological and clinical significance.

Authors:  B Paiva; N Puig; M T Cedena; B G de Jong; Y Ruiz; I Rapado; J Martinez-Lopez; L Cordon; D Alignani; J A Delgado; M C van Zelm; J J M Van Dongen; M Pascual; X Agirre; F Prosper; J I Martín-Subero; M-B Vidriales; N C Gutierrez; M T Hernandez; A Oriol; M A Echeveste; Y Gonzalez; S K Johnson; J Epstein; B Barlogie; G J Morgan; A Orfao; J Blade; M V Mateos; J J Lahuerta; J F San-Miguel
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

8.  Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.

Authors:  David F Moreno; Arturo Pereira; Natalia Tovar; María Teresa Cibeira; Laura Magnano; María Rozman; Mónica López-Guerra; Dolors Colomer; Beatriz Martín-Antonio; Raquel Jiménez-Segura; Ignacio Isola; Luis Gerardo Rodríguez-Lobato; Aina Oliver-Caldés; Mari Pau Mena; Laura Rosiñol; Joan Bladé; Carlos Fernández de Larrea
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

9.  Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.

Authors:  Jun Wang; Yuting Yan; Wenjie Xiong; Ge Song; Yi Wang; Jiawei Zhao; Yujiao Jia; Chengwen Li; Zhen Yu; Ying Yu; Jiawen Chen; Yang Jiao; Tingyu Wang; Rui Lyu; Qinghua Li; Yueshen Ma; Wei Liu; Dehui Zou; Gang An; Qi Sun; Huijun Wang; Zhijian Xiao; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Blood Adv       Date:  2022-07-12

10.  Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Authors:  V S Tompkins; R Sompallae; T R Rosean; S Walsh; M Acevedo; A L Kovalchuk; S-S Han; X Jing; C Holman; J E Rehg; S Herms; J S Sunderland; H C Morse; S Janz
Journal:  Blood Cancer J       Date:  2016-11-04       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.